Invasive Pituitary Adenomas: Significance of Proliferation Parameters

Pituitary

Volumn 2, Issue 2, 1999, Pages 117-122

  Amar, Arun Paul ^a,b   Hinton, David R ^a   Krieger, Mark D ^a   Weiss, Martin H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Neurosurgery ^*  (United States)

Author keywords

Pituitary adenoma; Pituitary carcinoma; Proliferation parameters; Tumor invasion; Tumor progression

Indexed keywords

TUMOR MARKER;

ADENOMA; ARTICLE; CANCER INVASION; CELL DIVISION; HUMAN; HYPOPHYSIS TUMOR; INCIDENCE; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS;

ADENOMA; CELL DIVISION; HUMANS; INCIDENCE; NEOPLASM INVASIVENESS; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033171011     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009931413106     Document Type: Article

References (43)

1. Scheithauer BW, Kovacs KT, Laws ER, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986;65:733-744.
2. Rosenblum ML, McKerrow J, Patel A, et al. Identification of a mechanism for brain invasion by malignant meningiomas and preliminary development of an anti-invasive therapy. 1992 Congress of Neurological Surgeons Annual Meeting (abstract).
3. Kaltsas GA, Grossman AB. Malignant pituitary tumors. Pituitary 1998;1:69-81.
4. Cusimano MD, Ohori P, Martinez AJ, Jungreis C, Wright DC. Pituitary carcinoma. Skull Base Surg 1994;4:46-51.
5. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer 1997;79:804-812.
6. Stewart PM, Carey MP, Graham CT, Wright AD, London DR. Growth hormone secreting pituitary carcinoma: A case report and literature review. Clin Endocrinol 1992;37: 189-195.
7. Popovic EA, Vattuone JR, Siu KH, Busmanis I, Pullar MJ, Dowling J. Malignant prolactinomas. Neurosurgery 1991;29: 127-130.
8. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427-1433.
9. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.
10. Bates AS, Farrell WE, Bicknell EJ, et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997;82:818-824.
11. th ed. New York: Oxford University Press, 1996;561-677.
12. Takino H, Herman V, Weiss M, Melmed S. Purine-binding factor (nm23) gene expression in pituitary tumors: Marker of adenoma invasiveness. J Clin Endocrinol Metab 1995;80: 1733-1738.
13. Buchfelder M, Fahlbusch R, Adams EF, Kiesewetter F, Thierauf P. Proliferation parameters for pituitary adenomas. Acta Neurochir 1996 (Suppl);65:18-21.
14. Doniach I. Pituitary carcinoma. Clin Endocrinol 1992; 37:194-195.
15. Selman WE, Laws ER, Scheithauer BW, Carpenter SM. The occurrence of durai invasion in pituitary adenomas. J Neurosurg 1986;64:402-407.
16. Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-107.
17. Sautner D, Saeger W. Invasiveness of pituitary adenomas. Path Res Pract 1991;187:632-636.
18. Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN. Chromosome 9p deletions in invasive and non-invasive nonfunctional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 1997;57:2703-2709.
19. Thapar K, Schiethauer BW, Kovacs K, Pernicone PJ, Laws EP. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-771.
20. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EFG-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 1995;81:656-662.
21. Ezzat S, Smyth HS, Raymar L, Asa SL. Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 1995;80:878-884.
22. Shimon I, Hinton DR, Weiss MH, Melmed S. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: Marker of tumor invasiveness. Clin Endocrinol 1998;48:23-29.
23. Clayton RN, Boggild M, Bates AS, Bicknell J, Simpson D, Farrell W. Tumor suppressor genes in the pathogenesis of human pituitary tumors. Hormone Res 1997;47:185-193.
24. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995;55:1613-1616.
25. q in invasive non-functional pituitary adenomas. Clin Endocrinol 1997;47:241-244.
26. Alvaro V, Levy L, Dubray C, et al. Invasive human pituitary tumors express a point-mutated alpha-protein kinase-C. J Clin Endocrinol Metab 1993;77:1125-1129.
27. Amar AP, DeArmond SJ, Spencer DR, Coopersmith PF, Ramos DM, Rosenblum ML. Development of an in vitro extracellular matrix assay for studies of brain tumor invasion. J Neuro-onc 1994;20:1-15.
28. Lei T, Xue D, Adams EF, Buchfelder M, Fahlbusch R. Relationship between invasiveness of pituitary somatotrophinomas and structural abnormalities of protein kinase C gene in human. J Tongji Med Univ 1997;17:68-71.
29. Thapar K, Kovacs K, Stefaneanu L, et al. Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors: An event associated with neoplastic progression and aggressive behavior. Am J Path 1997;151:769-784.
30. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir 1996;138:1442-1448.
31. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 1987;326:515-517..
32. Hsu DW, Hakim F, Biller BM, et al. Significance of proliferating cell nuclear antigen index in predicting adenoma recurrence. J Neurosurg 1993;78:753-761.
33. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices with tumor doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir 1996;138:1449-1455.
34. Ikeda H, Yoshimoto T. The relationship between c-myc protein expression, the bromodeoxyuridine labeling index and the biological behavior of pituitary adenomas. Acta Neuropathol 1992;83:361-364.
35. Pegolo G, Buckwalter JG, Weiss MH, Hinton DR. Pituitary adenomas: Correlation of the cytologie appearance with biologic behavior. Acta Cytol 1995;39:887-892.
36. Taylor WA, Uttley D, Wilkins PR. Multiple durai metastases from a pituitary adenoma: Case report. J Neurosurg 1994;81:624-626.
37. Rieger A, Rainov NG, Ebel H, et al. Factors predicting pituitary adenoma invasiveness in acromegalic patients. Neurosurg Rev 1997;20:182-187.
38. Fitzgibbons PL, Appley AJ, Turner RR, et al. Flow cytometric analysis of pituitary tumors: Correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer 1988;62:1556-1560.
39. Anniko M, Wersall J. DNA studies for prediction of prognosis of pituitary adenmas? Adv Biosci 1988;69:45-52.
40. Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg 1987;67:803-806.
41. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67. Neurosurgery 1989;25:927-930.
42. Daita G, Yonemasu Y. Durai invasion and proliferative potential of pituitary adenomas. Neurol Med-Chir 1996;36: 211-214.
43. Yonezawa K, Tamaki N, Kokunai T. Clinical features and growth fractions of pituitary adenomas. Surg Neurol 1997;48:494-500.